Sciwind Biosciences is a clinical-stage biopharmaceutical company led by Dr. Hai Pan that focuses on discovering and developing therapies to treat metabolic diseases. Its product pipeline centers on potentially first-in-class and best-in-class GLP-1 receptor agonism candidates. The company has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutics delivery platforms, and has identified multiple drug candidates based on those platforms. Lead programs include XW003 (a long-acting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once-weekly administration), XW004 (an oral formulation of XW003 suitable for once-daily oral administration) and XW014 (a small-molecule GLP-1R agonist intended for once-daily oral dosing). Sciwind raised $70M in a Series C to advance clinical development across these programs. Near-term clinical milestones include Phase 2 topline data for XW003 in the second half of 2022, Phase 1 entry for XW004 in Q4 2021 with topline expected H2 2022, and anticipated Phase 1 entry for XW014 in the first half of 2022. Sciwind Biosciences is a clinical-stage biopharmaceutical company focused on researching and developing innovative biologics targeting chronic metabolic and immunological diseases. Led by founder and CEO Hai Pan, Ph.D., the company has advanced multiple projects into clinical trials. A phase 1 clinical study of XW003 was completed at an overseas clinical site. Phase 2 trials for XW003 — targeting type II diabetes, obesity and non-alcoholic steatohepatitis (NASH) — were expected to be initiated in China in 2021. Sciwind also planned to file two additional IND applications in 2021, including an oral formulation of a highly active GLP-1 analogue. The company intends to use new funding to drive current clinical projects, advance other pipeline candidates into clinical development, and expand its talent team.

Total raised

$107M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2021